• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Catherine L. Nutt, B.S. Ph.D.


  • Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, Nutt CL, Iafrate AJ, Louis DN.A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.J Neuropathol Exp Neurol. 2011 Feb;70(2):110-5.
  • Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A.Increased expression of angiogenic genes in the brains of mouse meg3-null embryos.Endocrinology. 2010 Jun;151(6):2443-52.
  • Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL.Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.Acta Neuropathol. 2010 Apr;119(4):509-11.
  • Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K.A multigene predictor of outcome in glioblastoma.Neuro Oncology. 2010 Jan;12(1):49-57.
  • Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN.MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.Clin Cancer Res. 2009 Jul 15;15(14):4622-9.
  • Lun XQ,Jang JH,Tang N,Deng H,Head R,Bell JC,Stojdl DF,Nutt CL,Senger DL,Forsyth PA,McCart JA.Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.Clin Cancer Res. 2009 Apr 15;15(8):2777-88.
  • de la Iglesia N,Konopka G,Lim KL,Nutt CL,Bromberg JF,Frank DA,Mischel PS,Louis DN,Bonni A.Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.J Neurosci. 2008 Jun 4;28(23):5870-8.
  • Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL.Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8.
  • Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH, Louis DN.Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56.
  • Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN.Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.Oncogene. 2007 Jan 25;26(4):583-93.
  • Nutt CL.Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology.Neurosurg Focus. 2005 Nov;19(5):E2. Review.
  • Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH, Louis DN.Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma.J Neuropathol Exp Neurol. 2005 Nov;64(11):948-955.
  • Ma D, Nutt CL, Shanehsaz P, Peng X, Louis DN, Kaetzel DM.Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival i.Cancer Res. 2005 Jul 1;65(13):5523-34.
  • Mueller W, Mizoguchi M, Silen E, D'Amore K, Nutt CL, Louis DN.Mutations of the PIK3CA gene are rare in human glioblastoma.Acta Neuropathol. 2005 Jun;109(6):654-5.
  • Betensky RA, Nutt CL, Batchelor TT, Louis DN.Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers.J Mol Diagn. 2005 May;7(2):276-82.
  • Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO.YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.Clin Cancer Res. 2005 Mar 15;11(6):2258-64.
  • Mizoguchi M, Nutt CL, Mohapatra G, Louis DN.Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.Brain Pathol. 2004 Oct;14(4):372-7.
  • Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH.The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.J Neuropathol Exp Neurol. 2004 May;63(5):499-509.
  • Mizoguchi M, Nutt CL, Louis DN.Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma.Neurogenetics. 2004 Feb;5(1):81-2.
  • Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN.Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.Cancer Res. 2003 Apr 1;63(7):1602-7.
  • Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN.Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas.Cancer Res. 2003 Jan 15;63(2):413-6.
  • Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, Housman D.Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):916-21.
  • Nutt CL, Zerillo CA, Kelly GM, Hockfield S.Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats.Cancer Res. 2001 Oct 1;61(19):7056-9.
  • Nutt CL, Matthews RT, Hockfield S.Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican.Neuroscientist. 2001 Apr;7(2):113-22.
  • Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG.Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.Cancer Res. 2001 May 15;61(10):4155-9.
  • Nutt CL, Noble M, Chambers AF, Cairncross JG.Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.Cancer Res. 2000 Sep 1;60(17):4812-8.
  • Nutt CL, Loktionova NA, Pegg AE, Chambers AF, Cairncross JG.O(6)-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes.Carcinogenesis. 1999 Dec;20(12):2361-5.
  • Nutt CL, Chambers AF, Cairncross JG.Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absent of a p53-dependent cell cycle arrest.Cancer Res. 1996 Jun 15;56(12):2748-51.
  • Nutt CL, Costello JF, Bambrick LL, Yarosh DB, Swinnen LJ, Chambers AF, Cairncross JG.O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.Can J Neurol Sci. 1995 May;22(2):111-5.